Return to Results

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase

new search

Trial Conditions
  • Colorectal Neoplasms
What is the purpose of this trial?

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Date & Status


Who can Participate?


18 and older



Inclusion Criteria:

- History of Stage 0-III colon cancer with primary resection 1 year previously

- Patients with rectosigmoid cancers eligible if no RT administered

- One-year post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing
no evidence of disease

- Low risk or moderate risk of cardiovascular events

- At least 30 days from completion of adjuvant chemo.

- Presence of gastroesophageal reflux disease acceptable if controlled with medications

- Not receiving or planning to receive concomitant corticosteroids,nonsteroidal
anti-inflammatory drugs(NSAIDs), nor anticoagulants. Maximum aspirin dose

- 100 mg per day or ≤ two 325 mg tablets per week.

- Able to swallow oral medications

- Laboratory: WBC ≥ 4.0 x 103/mcL, platelets ≥ 100,000/mcL and hemoglobin > 11.0 g/dL.
Serum bilirubin ≤ 2.0 mg/dL and AST (SGOT) or ALT(SGPT) ≤ 2 x IULN. Serum creatinine
≤ 1.5 x IULN

- Zubrod PS 0-1, 18 years of age or older

- Will not participate in any other clinical trial for the treatment or prevention of
cancer unless off protocol treatment, on follow-up phase only

- Offered opportunity to participate in blood specimen banking

Exclusion Criteria:

- History of colon resection > 40 cm

- Mid-low rectal cancer

- Recurrent or metastatic disease

- High cardiovascular risk; Uncontrolled hypertension

- Planned radiation therapy or additional chemotherapy

- Documented history of gastric/duodenal ulcer within last 12 months and/or current
treatment or active symptoms of gastric/duodenal ulcer

- Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal
cancer, or inflammatory bowel disease

- ≥ 20 dB uncorrectable hearing loss for age of any two contiguous frequencies on
prestudy audiogram

- Known hypersensitivity to sulindac or excipient byproducts. Previous asthma,
urticaria, or allergic-type reaction to aspirin or other NSAIDs

- Significant medical or psychiatric condition that would preclude study completion (8

- No other prior malignancy except adequately treated basal cell or squamous cell skin
cancer, in situ cervical cancer, or other cancer for which the patient has been
disease-free for > 5 years

- Pregnant or nursing women. Women/men of reproductive potential must agree to use
effective contraception

Gender: Both
Steward Physician(s)
  • Jason A. Zell, D.O., MPH
  • St. Elizabeth's Medical Center - Recruiting
Trial Interventions
  • Eflornithine placebo & sulindac placebo
  • eflornithine & sulindac placebo
  • Eflornithine placebo & sulindac
  • Eflornithine plus sulindac
For more information about this trial, contact

Olga Kozyreva

Phone: (617) 789-2903

Physician Researcher

Investigator Name:

  • Jason A. Zell, D.O., MPH

Other Information

Sponsor: Southwest Oncology Group
Phase: Phase 3
Trial ID: NCT01349881
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Share This Page Print This Page

Subscribe to Believe

Our electronic health news
Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions